PAREXEL has launched a new service to provide real-world data insights to help life science companies more effectively demonstrate product value. The new offering will leverage real-world data strategies designed to accelerate market access and mitigate commercial risk by addressing key factors necessary to demonstrate a product’s value during late-stage development, as well as before and after launch.

PAREXEL has established a dedicated real-world data service team with expertise in epidemiology, health economics and outcomes research, market access, analytics, medical sciences, and safety. The group is an expansion of the PAREXEL Access unit, which provides evidence-based services throughout the product lifecycle.
 
“In an increasingly competitive market, leveraging data to demonstrate value is critical. However, unstructured data can make it difficult to overcome gaps in real-world evidence,” said Joshua Schultz, Senior Vice President and Worldwide Head of PAREXEL Access. “Our new service will allow clients to more seamlessly collect and communicate the specific data that payers, physicians, and patients require to establish that a new product offers greater benefits than the existing standard of care.”